Sugi Predict

Sugi Predict / Compounds / SCHEMBL2350309

SCHEMBL2350309

SCHEMBL2350309

CCCC(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ THRB P10828 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ NFKB1 P19838 1/20 0.59
▸ PTGS2 P35354 1/20 0.59
▸ THPO P40225 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ ACE P12821 1/20 0.53
▸ FNTA P49354 4/20 0.51
▸ FNTB P49356 4/20 0.51
▸ FOLH1 Q04609 1/20 0.50
▸ NOD1 Q9Y239 4/20 0.49
▸ PTGS1 P23219 1/20 0.43
▸ GSTK1 Q9Y2Q3 1/20 0.43
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350303 1.00 KDM4E (0.59) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4321775 1.00 KDM4E (0.59) KDM4EMAPTTHRBALOX15NFKB1
Ammonia Solution, Strong SCHEMBL10400612 0.98 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27577753 0.90 KDM4E (0.53) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL5867431 0.89 NOD1 (0.58) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL5867434 0.89 NOD1 (0.58) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4990899 0.87 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2356282 0.87 NOD1 (0.66) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2356288 0.87 NOD1 (0.66) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL25187792 0.85 NOD1 (0.69) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379214-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING SAME L'OREAL, S.A. (FR) 2004-01-14 — — EP claimed
US-20020159962-A1 Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same L'OREAL S.A. (FR) 2002-10-31 — — US claimed
WO-2002067875-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING THE SAME L'OREAL S.A. (FR) 2002-09-06 — — WO claimed
US-4859653-A Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin MORELLE JEAN V (FR) 1989-08-22 — — US claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 — — US disclosed
WO-2024205472-A1 COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF HUMAN TRANSTHYRETIN AMYLOIDOSIS OLOFSSON ANDERS (SE) 2024-10-03 — — WO disclosed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 — — EP disclosed
CN-118488855-A Solid composition comprising peptide or protein and acylated amino acid 阿道恰公司 2024-08-13 — — CN disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 — — EP disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 — — WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 — — EP disclosed
US-11632972-B2 S-nitrosothiol compounds and their combinations with nitrosamine blocking agents for safe food preservation YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-04-25 — — US disclosed
EP-0317540-B1 CYSTEINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE Aktiebolaget Draco (SE) 1992-08-12 — — EP disclosed
EP-0304778-B1 PROCESS FOR THE PRODUCTION OF N-ACYLATED MERCAPTO-ALPHA-AMINO ACIDS Degussa Aktiengesellschaft (DE) 1991-10-23 — — EP disclosed
US-4992267-A Mixture of alkali metal hydroxide and disulfide reducing agent JOHNSON PRODUCTS CO., INC. (US) 1991-02-12 — — US disclosed
WO-1990013538-A1 ORGANIC SALTS OF CYSTEINE DERIVATIVES AKTIEBOLAGET DRACO (SE) 1990-11-15 — — WO disclosed
US-4918223-A Method of preparing N-acylated mercapto-alpha-amino acids DEGUSSA AKTIENGESELLSCHAFT (DE) 1990-04-17 — — US disclosed
WO-1989004825-A1 NEW DERIVATIVES OF CYSTEINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AKTIEBOLAGET DRACO (SE) 1989-06-01 — — WO disclosed
EP-0317540-A1 Cysteine derivatives, processes for their preparation and their use Aktiebolaget Draco (SE) 1989-05-24 — — EP disclosed
EP-0304778-A1 Process for the production of N-acylated mercapto-alpha-amino acids Degussa Aktiengesellschaft (DE) 1989-03-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP KDM4E 2561/4885MAPT 2383/4885THRB 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.